Literature DB >> 31696961

Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission.

Kelly C Cushing1,2,3, William Tan1,2, David H Alpers4, Vikram Deshpande2,5, Ashwin N Ananthakrishnan1,2.   

Abstract

BACKGROUND: Clinical and endoscopic remission are treatment targets in ulcerative colitis (UC). The value of histologic healing in altering clinical outcomes among patients with complete endoscopic healing is not well established. AIM: To quantify the association between histologic activity and clinical relapse among patients with UC who were in complete endoscopic remission.
METHODS: This study included patients with UC from a prospective registry who were in complete endoscopic remission. Histologic activity was quantified by a senior gastrointestinal pathologist. Histologic activity was defined as lack of normalisation (Geboes score > 0) as well as histologically active disease (Geboes score ≥2.1 and ≥3.1). The primary outcome was clinical relapse within 2 years. Multivariable regression adjusting for potential confounders examined the independent predictive value of histologic changes.
RESULTS: The study included 83 patients (51% women) (median age 44 years; median disease duration 11 years). Forty-one (49%) had complete histologic normalisation. Within two years, 26 (31%) experienced clinical relapse. Patients with complete histologic normalisation were less likely to experience relapse (5/41, 12%) compared to those without normalisation (21/42, 50%, P < 0.001) (multivariable OR 7.22, 95% confidence interval (CI) 2.48-24.70) by the Geboes score. The individual components of the Geboes score predictive of relapse were architectural changes (P = 0.03) and increased chronic inflammatory infiltrate (P < 0.001).
CONCLUSIONS: Complete histologic healing using the Geboes score was associated with reduced rates of clinical relapse among patients with UC in endoscopic remission.
© 2019 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2019        PMID: 31696961      PMCID: PMC6980269          DOI: 10.1111/apt.15568

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  38 in total

1.  Development and validation of the Nancy histological index for UC.

Authors:  Aude Marchal-Bressenot; Julia Salleron; Camille Boulagnon-Rombi; Claire Bastien; Virginie Cahn; Guillaume Cadiot; Marie-Danièle Diebold; Silvio Danese; Walter Reinisch; Stefan Schreiber; Simon Travis; Laurent Peyrin-Biroulet
Journal:  Gut       Date:  2015-10-13       Impact factor: 23.059

2.  An endoscopic Mayo score of 0 is associated with a lower risk of colectomy than a score of 1 in ulcerative colitis.

Authors:  Claire Manginot; Cédric Baumann; Laurent Peyrin-Biroulet
Journal:  Gut       Date:  2014-12-30       Impact factor: 23.059

Review 3.  Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat?

Authors:  Manasi Agrawal; Jean-Frederic Colombel
Journal:  Gastrointest Endosc Clin N Am       Date:  2019-04-06

4.  Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial.

Authors:  Vipul Jairath; Laurent Peyrin-Biroulet; Guangyong Zou; Mahmoud Mosli; Niels Vande Casteele; Reetesh K Pai; Mark A Valasek; Aude Marchal-Bressenot; Larry W Stitt; Lisa M Shackelton; Reena Khanna; Geert R D'Haens; William J Sandborn; Allan Olson; Brian G Feagan; Rish K Pai
Journal:  Gut       Date:  2018-08-03       Impact factor: 23.059

5.  Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis.

Authors:  Sandro Ardizzone; Andrea Cassinotti; Piergiorgio Duca; Cristina Mazzali; Chiara Penati; Gianpiero Manes; Riccardo Marmo; Alessandro Massari; Paola Molteni; Giovanni Maconi; Gabriele Bianchi Porro
Journal:  Clin Gastroenterol Hepatol       Date:  2010-12-31       Impact factor: 11.382

6.  Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes.

Authors:  Britt Christensen; Stephen B Hanauer; Jonathan Erlich; Olufemi Kassim; Peter R Gibson; Jerrold R Turner; John Hart; David T Rubin
Journal:  Clin Gastroenterol Hepatol       Date:  2017-02-24       Impact factor: 11.382

7.  Histologic markers of inflammation in patients with ulcerative colitis in clinical remission.

Authors:  Laura Rosenberg; Kavinderjit S Nanda; Talia Zenlea; Anne Gifford; Garrett O Lawlor; Kenneth R Falchuk; Jacqueline L Wolf; Adam S Cheifetz; Jeffrey D Goldsmith; Alan C Moss
Journal:  Clin Gastroenterol Hepatol       Date:  2013-04-13       Impact factor: 11.382

Review 8.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

9.  A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review.

Authors:  Ryan Ungaro; Jean-Frédéric Colombel; Trevor Lissoos; Laurent Peyrin-Biroulet
Journal:  Am J Gastroenterol       Date:  2019-06       Impact factor: 10.864

10.  Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis With Endoscopically Normal Mucosa.

Authors:  Ryo Ozaki; Taku Kobayashi; Shinji Okabayashi; Masaru Nakano; Shojiroh Morinaga; Atsuko Hara; Makoto Ohbu; Kentaro Matsuoka; Takahiko Toyonaga; Eiko Saito; Tadakazu Hisamatsu; Toshifumi Hibi
Journal:  J Crohns Colitis       Date:  2018-11-15       Impact factor: 9.071

View more
  13 in total

1.  Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Authors:  Hyuk Yoon; Sushrut Jangi; Parambir S Dulai; Brigid S Boland; Larry J Prokop; Vipul Jairath; Brian G Feagan; William J Sandborn; Siddharth Singh
Journal:  Gastroenterology       Date:  2020-06-22       Impact factor: 22.682

Review 2.  Artificial Intelligence for Disease Assessment in Inflammatory Bowel Disease: How Will it Change Our Practice?

Authors:  Ryan W Stidham; Kento Takenaka
Journal:  Gastroenterology       Date:  2022-01-04       Impact factor: 22.682

3.  Risk of Relapse in Patients With Ulcerative Colitis With Persistent Endoscopic Healing: A Durable Treatment Endpoint.

Authors:  Sushrut Jangi; Ariela K Holmer; Parambir S Dulai; Brigid S Boland; Angelina E Collins; Lysianne Pham; William J Sandborn; Siddharth Singh
Journal:  J Crohns Colitis       Date:  2021-04-06       Impact factor: 9.071

4.  Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission.

Authors:  Hyuk Yoon; Sushrut Jangi; Parambir S Dulai; Brigid S Boland; Vipul Jairath; Brian G Feagan; William J Sandborn; Siddharth Singh
Journal:  Inflamm Bowel Dis       Date:  2021-07-27       Impact factor: 5.325

5.  An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.

Authors:  Christopher Ma; Rocio Sedano; Ahmed Almradi; Niels Vande Casteele; Claire E Parker; Leonardo Guizzetti; David F Schaeffer; Robert H Riddell; Reetesh K Pai; Robert Battat; Bruce E Sands; Christophe Rosty; Marla C Dubinsky; Florian Rieder; Noam Harpaz; Maria T Abreu; Robert V Bryant; Gregory Y Lauwers; Richard Kirsch; Mark A Valasek; Eileen Crowley; William J Sandborn; Brian G Feagan; Rish K Pai; Vipul Jairath
Journal:  Gastroenterology       Date:  2021-02-19       Impact factor: 22.682

6.  Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing.

Authors:  Sushrut Jangi; Hyuk Yoon; Parambir S Dulai; Mark Valasek; Brigid S Boland; Vipul Jairath; Brian G Feagan; William J Sandborn; Siddharth Singh
Journal:  Aliment Pharmacol Ther       Date:  2020-08-09       Impact factor: 8.171

7.  Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis.

Authors:  Sushrut Jangi; Ariela K Holmer; Parambir S Dulai; Brigid Boland; Mark Valasek; Vipul Jairath; Brian G Feagan; William J Sandborn; Siddharth Singh
Journal:  Clin Gastroenterol Hepatol       Date:  2021-02-06       Impact factor: 13.576

8.  PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis.

Authors:  Olga Maria Nardone; Alina Bazarova; Pradeep Bhandari; Rosanna Cannatelli; Marco Daperno; Jose Ferraz; Martin Goetz; Xianyong Gui; Bu Hayee; Gert De Hertogh; Mark Lazarev; Ji Li; Adolfo Parra-Blanco; Luca Pastorelli; Remo Panaccione; Vincenzo Occhipinti; Timo Rath; Samuel C L Smith; Uday N Shivaji; Gian Eugenio Tontini; Michael Vieth; Vincenzo Villanacci; Davide Zardo; Raf Bisschops; Ralf Kiesslich; Subrata Ghosh; Marietta Iacucci
Journal:  United European Gastroenterol J       Date:  2022-02-23       Impact factor: 4.623

9.  Induction of mucosal healing by intensive granulocyte/monocyte adsorptive apheresis (GMA) without use of corticosteroids in patients with ulcerative colitis: long-term remission maintenance after induction by GMA and efficacy of GMA re-treatment upon relapse.

Authors:  Takumi Fukuchi; Kousaku Kawashima; Hideaki Koga; Ran Utsunomiya; Kohei Sugiyama; Keiji Shimazu; Takaaki Eguchi; Shunji Ishihara
Journal:  J Clin Biochem Nutr       Date:  2021-12-25       Impact factor: 3.114

Review 10.  Endoscopic and Histologic Predictors of Outcomes in Pediatric Ulcerative Colitis-Caveat Emptor.

Authors:  Lorraine Stallard; Séamus Hussey
Journal:  Front Pediatr       Date:  2021-06-23       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.